SOLIGENIX, INC.
No SEC Form 4 filings for $SNGX in the last 30 days.
See all $SNGX insider activity →LCID, SNGX, and SRAD hit 52-week lows. LCID faces production and loss challenges, SNGX's cancer trial halted, SRAD reports Q1 loss despite revenue growth. LCID projects Q1 revenue of $280M-$284M and a $1B operating loss. SNGX has $5.9M cash, exploring options. SRAD maintains full-year outlook, but faces price target cut and short interest.
Soligenix terminated the Phase III FLASH2 trial for its topical CTCL therapy HyBryte (SGX301/synthetic hypericin sodium) after interim analysis indicated it was unlikely to meet primary goals. The company will shift focus to dusquetide for Behçet’s disease and pursue commercial opportunities for its ThermoVax vaccine platform. The article also notes CTCL drug approvals and sales figures.
Soligenix (Nasdaq: SNGX) reported no revenue for the quarter ended June 30, 2026. Net loss was $2.0 million, or ($0.12) per share, versus $2.7 million, or ($0.82) per share, a year earlier. The company said it discontinued its HyBryte (synthetic hypericin) Phase 3 FLASH2 program after a futility recommendation. Cash was about $9.8 million as of June 30, 2026.
Over the past 7 days, alphai's AI scored 1 news story mentioning SNGX (SOLIGENIX, INC.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent SNGX coverage spans financial news, market movers and earnings.
Trial halt creates significant downside risk for the biotech.
HyBryte is being discontinued, reducing near-term CTCL upside and likely pressuring sentiment and valuation while capital focus moves to dusquetide and ThermoVax.
The FLASH2 discontinuation and cash runway disclosure shift near-term risk toward pipeline execution and potential non-dilutive funding.
Near-term risk is Nasdaq delisting mechanics (180-day cure window, possible reverse split) alongside clinical/program value reset from HyBryte™ termination.
Ebola-strain applicability work can re-rate ThermoVax platform expectations and potential program funding/partnership interest.
alphai scores every news story that mentions SNGX with an AI model for sentiment and relevance, and aggregates insider trades from SOLIGENIX, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
LCID, SNGX, and SRAD hit 52-week lows. LCID faces production and loss challenges, SNGX's cancer trial halted, SRAD reports Q1 loss despite revenue growth. LCID projects Q1 revenue of $280M-$284M and a $1B operating loss. SNGX has $5.9M cash, exploring options. SRAD maintains full-year outlook, but faces price target cut and short interest.
2 min readSoligenix terminated the Phase III FLASH2 trial for its topical CTCL therapy HyBryte (SGX301/synthetic hypericin sodium) after interim analysis indicated it was unlikely to meet primary goals. The company will shift focus to dusquetide for Behçet’s disease and pursue commercial opportunities for its ThermoVax vaccine platform. The article also notes CTCL drug approvals and sales figures.
6 min readSoligenix (Nasdaq: SNGX) reported no revenue for the quarter ended June 30, 2026. Net loss was $2.0 million, or ($0.12) per share, versus $2.7 million, or ($0.82) per share, a year earlier. The company said it discontinued its HyBryte (synthetic hypericin) Phase 3 FLASH2 program after a futility recommendation. Cash was about $9.8 million as of June 30, 2026.
6 min readSOLIGENIX, INC. (SNGX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Soligenix, Inc._June 10, 2026 0000812796 false DE 0000812796 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Ea
3 min readBiotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).
6 min readSoligenix, Inc. (SNGX) boasts a robust late-stage pipeline, featuring assets like HyBryte for CTCL, which target rare diseases and critical public health threats. The company's efforts are supported by strong clinical data, significant market potential, government funding, and experienced leadership. This positions SNGX for ongoing development and commercialization in these key therapeutic areas.
3 min readSoligenix (NASDAQ: SNGX) announced positive results from a comparability study published in Oncology and Therapy, evaluating HyBryte versus Valchlor for cutaneous T-cell lymphoma (CTCL). The study showed that 60% of HyBryte-treated patients achieved treatment success after 12 weeks, compared to 20% for Valchlor, with HyBryte demonstrating greater improvement and no treatment-related adverse events. These findings suggest HyBryte is a well-tolerated and effective potential therapy for early-stage CTCL.
3 min readSoligenix Inc. (NASDAQ:SNGX) stock rose after reporting positive Phase 2a study results for SGX945 in treating oral ulcers associated with Behçet’s Disease, with beneficial effects persisting post-treatment. The company plans to reformulate SGX945 for home-based use, addressing a significant unmet medical need for Behçet’s Disease patients worldwide.
2 min readSoligenix stock jumps more than 67% after receiving the FDA orphan drug designation for dusquetide. Orphan status brings market exclusivity, tax credits, grants and fee waivers. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here →
2 min readAUSTIN, Texas, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- via IBN - NetworkNewsAudio announces the Audio Press Release ( APR ) titled "Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas," featuring Soligenix Inc. SNGX.
2 min read
